Linkedin
Facebook
Twitter
Youtube

23 Feb Mammoth Biosciences

Posted at 19:25h in by

Peter Nell, Ph.D., Chief Business Officer and Head of Therapeutics

Oct. 14 | 9:15am | BlueRock Therapeutics Ballroom

Brisbane, CA

(Private)

In-person Presentation

Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. With a distinguished team, including co-founder and Nobel Laureate Jennifer Doudna, Mammoth is discovering novel CRISPR systems enabling the full potential to read and write the code of life. Mammoth’s efforts are focused on CRISPR-based diagnostics applying its proprietary DETECTR™ platform, and on differentiated gene editing approaches towards ex vivo and in vivo therapeutics benefiting from our proprietary CRISPR systems with unique characteristics. The company is establishing a pipeline of partnered and in-house programs to advance disease detection and treatment.

www.mammoth.bio



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,200 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 11-13, 2022
Carlsbad, CA

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions